--- title: "The policy side clearly optimizes the pricing mechanism for innovative drugs, focusing on the window for innovative drug layout in the Hong Kong stock market" type: "News" locale: "en" url: "https://longbridge.com/en/news/282791729.md" description: "On April 15th, with favorable policies and a rebound in market risk appetite, the innovative drug sector became active. The E Fund Hang Seng SCHK Innovative Drug ETF (159316) rose by 3.72%, and the E Fund CSI Innovative Drugs ETF (516080) increased by 2.07%. The General Office of the State Council issued opinions on the formation mechanism of drug prices, proposing 14 measures to support the pricing of high-level innovative drugs, marking a policy shift to a new stage of full lifecycle and classified measures, which is beneficial for the expansion of the commercialization space for innovative drugs. It is recommended to pay attention to the E Fund Hang Seng SCHK Innovative Drug ETF (159316) and the E Fund CSI Innovative Drugs ETF (516080)" datetime: "2026-04-15T05:59:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282791729.md) - [en](https://longbridge.com/en/news/282791729.md) - [zh-HK](https://longbridge.com/zh-HK/news/282791729.md) --- # The policy side clearly optimizes the pricing mechanism for innovative drugs, focusing on the window for innovative drug layout in the Hong Kong stock market On April 15, with favorable policies and a rebound in market risk appetite, the innovative drug sector became active. As of 1:35 PM, **E Fund Hang Seng SCHK Innovative Drug ETF (159316)** rose by 3.72%, and **E Fund CSI Innovative Drugs ETF (516080)** increased by 2.07%. In terms of individual stocks, **Borui Pharmaceutical (688166.SH)** hit the daily limit up of 20%, while **BeiGene-U (688235.SH)**, **Tonghua Dongbao (600867.SH)**, **Rongchang Bio (688331.SH)**, **Buchang Pharmaceutical (603858.SH)**, **Junshi Biosciences-U (688180.SH)**, **Dizal Pharmaceutical-U (688192.SH)**, **Sanofi (688336.SH)**, and **Baili Tianheng (688506.SH)** all rose over 4%, with **Kelun Pharmaceutical (002422.SZ)** also following suit. On the news front, on April 14, the General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism of Pharmaceuticals," proposing 14 measures, including optimizing the initial pricing mechanism for innovative drugs and other newly listed drugs, leveraging the guiding role of medical insurance payment standards in drug price formation, guiding pharmacies to reasonably set retail prices for drugs, and strengthening the supply and price stability of shortage drugs. According to the opinions, the pricing of newly listed drugs will distinguish between high-level innovative drugs, improved new drugs, and generic drugs (i.e., copy drugs), providing policy support and guidance accordingly. For high-level innovative drugs with high innovation and clinical value, support will be given to set prices in the early stages of listing that correspond to high investment and high risk, maintaining relatively stable prices for a certain period. After 11 years, the national level has once again issued a programmatic document on drug pricing issues in the name of the General Office of the State Council, marking a shift in policy from "cost control as the main focus" to a new stage of price governance that encompasses the entire lifecycle, classified policies, and a unified national market. This is beneficial for innovative drugs to expand more commercial space domestically, significantly raising the ceiling of the domestic innovative drug market. To seize the opportunity of policy catalysis, attention can be paid to: **E Fund Hang Seng SCHK Innovative Drug ETF (159316)**, which has lower fees, focuses on core targets of Hong Kong innovative drugs, and fully benefits from policy warming and valuation recovery; **E Fund CSI Innovative Drugs ETF (516080)**: covering leading A-share innovative drug companies, allowing for a one-click layout of the domestic innovative drug industry's growth dividends ### Related Stocks - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [516080.CN](https://longbridge.com/en/quote/516080.CN.md) - [688166.CN](https://longbridge.com/en/quote/688166.CN.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [600867.CN](https://longbridge.com/en/quote/600867.CN.md) - [688331.CN](https://longbridge.com/en/quote/688331.CN.md) - [09995.HK](https://longbridge.com/en/quote/09995.HK.md) - [603858.CN](https://longbridge.com/en/quote/603858.CN.md) - [688180.CN](https://longbridge.com/en/quote/688180.CN.md) - [01877.HK](https://longbridge.com/en/quote/01877.HK.md) - [688192.CN](https://longbridge.com/en/quote/688192.CN.md) - [688336.CN](https://longbridge.com/en/quote/688336.CN.md) - [688506.CN](https://longbridge.com/en/quote/688506.CN.md) - [002422.CN](https://longbridge.com/en/quote/002422.CN.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [02615.HK](https://longbridge.com/en/quote/02615.HK.md) ## Related News & Research - [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md) - [VanEck, Grayscale file fresh BNB ETF amendments as race for next altcoin spot ETF accelerates](https://longbridge.com/en/news/286652991.md) - [1 Rapidly Deteriorating ETF Screams That ‘Shop ‘Til You Drop’ Americans Have All But Keeled Over](https://longbridge.com/en/news/286429552.md) - [Worried About a Market Crash? 3 Vanguard ETFs Built to Survive](https://longbridge.com/en/news/286880525.md) - ['Biggest bottleneck in the AI buildup' fuels DRAM ETF to record](https://longbridge.com/en/news/286596736.md)